市场调查报告书
商品编码
1470568
肝病诊断市场:按诊断技术和最终用户划分 - 全球预测 2024-2030Liver Disease Diagnostics Market by Diagnosis Technique (Biopsy, Endoscopy, Imaging), End-user (Hospitals, Laboratories) - Global Forecast 2024-2030 |
※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。
预计2023年肝病诊断市场规模为99.4亿美元,预计2024年将达110.9亿美元,2030年将达到230.5亿美元,复合年增长率为12.76%。
肝病诊断市场包括专门用于检测和监测各种肝病(如肝炎、肝硬化、肝癌和非酒精性脂肪肝)的所有技术、产品和服务。主要目标是促进肝臟相关疾病的早期发现、准确分期和有效管理。肝病盛行率不断上升,人们的认识和预防方法不断提高,以及各地区医疗基础设施的改善,使得肝病诊断解决方案的采用成为必要。此外,政府对肝病监测和管理的努力和资助正在增加对肝病诊断的需求。然而,肝病诊断面临挑战,例如先进诊断测试成本高、肝病诊断标准不一致以及资源匮乏地区的获取机会有限。此外,缺乏某些肝臟疾病的特异性生物标记以及与侵入性诊断程序相关的风险可能会阻碍生长。然而,主要参与者正在探索非侵入性成像技术和生物标记发现等尖端发展,以避免技术和安全併发症。此外,人工智慧和机器学习在诊断中的日益集成,有望提高准确性和预测分析能力,也开闢了新的成长途径。个人化医疗和基因组学也越来越受到关注,为客製化诊断和治疗方法提供了潜力。
主要市场统计 | |
---|---|
基准年[2023] | 99.4亿美元 |
预测年份 [2024] | 110.9亿美元 |
预测年份 [2030] | 230.5亿美元 |
复合年增长率(%) | 12.76% |
诊断技术:诊断肝臟疾病的影像方法不断进步
肝臟切片检查是取出一小部分肝组织并在显微镜下观察的过程。切片检查对于诊断某些血液检查或影像学检查无法检测到的肝臟疾病以及确定肝损伤的程度非常重要。当需要分析C型肝炎等慢性疾病造成的肝损伤程度,或需要诊断原因不明的肝臟异常时,通常会建议进行切片检查。用于肝臟诊断的内视镜检查通常是指称为内视镜逆行性造影的手术,用于检查胆管。它可以识别与胆管阻塞和肝臟疾病相关的异常。当医生怀疑有影响胆管的疾病或需要移除胆管结石时,通常会进行内视镜检查。诊断影像,包括超音波、电脑断层扫描和磁振造影,可以提供肝臟的详细影像,有助于诊断脂肪肝、肿瘤和肝硬化等疾病。诊断影像是一种第一线非侵入性诊断技术,通常在需要目视评估肝臟结构和检测肿块时使用。实验室检查可以透过分析血液样本来帮助诊断肝病。常见的测试包括肝酵素测试,如丙氨酸转氨酶(ALT)测试和天门冬胺基转移酶(AST)测试、胆红素测试、白蛋白测试、血液凝固检查和病毒性肝炎测试。实验室检查通常是诊断肝病的第一步,用于常规筛检、监测疾病进展和评估治疗效果。
最终用户在政府措施的支持下进行全球医院扩张,以发展强大的医疗保健基础设施
医院是肝病诊断的重要最终使用者。医院通常拥有先进的诊断设备,并配备专门的医疗保健专业人员。肝病患者通常需要立即进行综合治疗,而医院通常能够提供这些治疗。这包括一系列诊断测试,如血液测试、影像和切片检查,以确认肝炎、肝硬化和肝癌等诊断。医院通常根据需求而受到高度青睐,因为它们能够提供从诊断到治疗的一体化服务,包括紧急医疗护理、手术和术后追踪。诊断服务与治疗的结合是病人选择医院诊断的一个令人信服的理由。实验室,无论是独立的还是附属于诊所的,都专门分析血液和组织样本以检测肝臟异常。与医院相比,检测设施位置便利,诊断检测所需时间更短。该实验室主要满足诊断和监测肝病所需的常规筛检和血液检测的需要。
区域洞察
架构地区以美国和加拿大为中心,具有强大的医疗保健结构和对各种疾病有利的报销政策,促进了肝病诊断的发展。非侵入性成像技术和生物标记识别领域的创新正在获得大量投资和专利申请。美国肝臟基金会为改善肝臟健康所做的努力等措施反映了该领域的积极努力。欧盟(EU)根据其成员国的不同,拥有不同的医疗保健系统和经济实力,因此消费者行为也多种多样。然而,欧洲肝臟研究协会临床实践指南的采用是肝臟疾病诊断标准化的重要因素。不断增加的研发支出和多边合作(例如欧盟的地平线 2020 计画)展现了该地区充满活力的创新环境。在亚太地区,由于肝臟相关疾病的盛行率不断增加、人们对肝臟健康的认识不断提高,以及政府努力将医疗设施扩展到马苏,因此对肝臟疾病诊断的需求正在迅速增加。此外,亚太地区越来越多地采用数位医疗服务和解决方案,这可以为该行业提供新的成长途径。
FPNV定位矩阵
FPNV定位矩阵对于评估肝病诊断市场至关重要。我们检视与业务策略和产品满意度相关的关键指标,以对供应商进行全面评估。这种深入的分析使用户能够根据自己的要求做出明智的决策。根据评估,供应商被分为四个成功程度不同的像限:前沿(F)、探路者(P)、利基(N)和重要(V)。
市场占有率分析
市场占有率分析是一种综合工具,可以对肝病诊断市场供应商的现状进行深入而深入的研究。全面比较和分析供应商在整体收益、基本客群和其他关键指标方面的贡献,以便更好地了解公司的绩效及其在争夺市场占有率时面临的挑战。此外,该分析还提供了对该行业竞争特征的宝贵见解,包括在研究基准年观察到的累积、分散主导地位和合併特征等因素。这种详细程度的提高使供应商能够做出更明智的决策并制定有效的策略,从而在市场上获得竞争优势。
1. 市场渗透率:提供有关主要企业所服务的市场的全面资讯。
2. 市场开拓:我们深入研究利润丰厚的新兴市场,并分析其在成熟细分市场的渗透率。
3. 市场多元化:提供有关新产品发布、开拓地区、最新发展和投资的详细资讯。
4.竞争评估与资讯:对主要企业的市场占有率、策略、产品、认证、监管状况、专利状况、製造能力等进行全面评估。
5. 产品开发与创新:提供对未来技术、研发活动和突破性产品开发的见解。
1.肝病诊断市场的市场规模与预测是多少?
2.肝病诊断市场预测期内需要考虑投资的产品、细分市场、应用及领域有哪些?
3.肝病诊断市场的技术趋势与法规结构是什么?
4.肝病诊断市场主要厂商的市场占有率是多少?
5.进入肝病诊断市场合适的型态和策略手段是什么?
[194 Pages Report] The Liver Disease Diagnostics Market size was estimated at USD 9.94 billion in 2023 and expected to reach USD 11.09 billion in 2024, at a CAGR 12.76% to reach USD 23.05 billion by 2030.
The liver disease diagnostics market encompasses all technologies, products, and services dedicated to detecting and monitoring various liver conditions, including hepatitis, cirrhosis, liver cancer, and non-alcoholic fatty liver disease. The primary goal is to promote early detection, accurate staging, and effective management of liver-related diseases. The rising prevalence of liver diseases, increased awareness and preventive approaches, and improvements in healthcare infrastructure across various regions have necessitated the adoption of liver disease diagnostics solutions. Additionally, supportive government initiatives and funding for liver disease research and management accentuate the need for liver disease diagnostics. However, liver disease diagnostics faces challenges related to the high costs of advanced diagnostic tests, discrepancies in liver disease diagnostic standards, and limited accessibility in low-resource settings. Moreover, the lack of specific biomarkers for certain liver diseases and the risks associated with invasive diagnostic procedures can hinder growth. However, key players are exploring cutting-edge developments such as non-invasive imaging technologies and biomarker discovery to circumvent technical and safety complications. Furthermore, the increasing integration of AI and ML in diagnostics, which promises enhanced accuracy and predictive analytics, also opens up new avenues for growth. Personalized medicine and genomics are also gaining traction, offering the potential for tailored diagnostic and therapeutic approaches.
KEY MARKET STATISTICS | |
---|---|
Base Year [2023] | USD 9.94 billion |
Estimated Year [2024] | USD 11.09 billion |
Forecast Year [2030] | USD 23.05 billion |
CAGR (%) | 12.76% |
Diagnosis Technique: Ongoing advances to improve imaging modalities for liver disease diagnosis
A liver biopsy is a process that involves the removal of a small section of liver tissue, which is then examined under a microscope. Biopsies can be crucial in diagnosing certain liver diseases that are not detectable through blood tests or imaging and in determining the degree of liver damage. Biopsies are often recommended when it is necessary to analyze the severity of liver damage in chronic conditions such as hepatitis C or to diagnose unexplained liver abnormalities. Endoscopy for liver diagnostics most often refers to a procedure known as endoscopic retrograde cholangiopancreatography, which is used to examine the bile ducts. It can identify blockages or abnormalities connected with liver diseases. Endoscopy is typically used when there is a suspicion of diseases that affect the bile ducts or when there's a need to extract bile duct stones. Imaging techniques include ultrasound, computed tomography scan, magnetic resonance imaging, and other modalities that provide detailed pictures of the liver and can help diagnose conditions like fatty liver, tumors, and cirrhosis. Imaging is the first line of non-invasive diagnostic techniques often used when there's a need for a visual assessment of the liver structure and detection of masses. Laboratory tests help in the diagnosis of liver diseases through the analysis of blood samples. Common tests include liver enzyme tests such as the alanine transaminase (ALT) test, aspartate aminotransferase (AST) test, bilirubin tests, albumin tests, clotting tests, and viral hepatitis tests. Laboratory tests are usually the first step in diagnosing liver disease and are used for routine screening, monitoring of disease progression, and evaluating treatment efficacy.
End-user: Expansion of hospitals across the world supported by government initiatives for developing robust healthcare infrastructure
Hospitals represent a significant end-user for liver disease diagnostics. They are typically equipped with advanced diagnostic equipment and staffed by specialized healthcare professionals. Patients with liver diseases often require immediate and comprehensive care, which hospitals are usually able to provide. This includes a series of diagnostic tests such as blood tests, imaging, and biopsies to confirm the diagnosis of conditions such as hepatitis, cirrhosis, or liver cancer. The need-based preference for hospitals is generally high due to their ability to offer a full spectrum of services from diagnosis to treatment, including emergency care, surgery, and post-operative follow-ups. The integration of diagnostic services with therapeutic care is a compelling reason for patients to choose hospital-based diagnostics. Laboratories, either standalone or those associated with clinics, specialize in the analysis of blood and tissue samples to detect liver abnormalities. Compared to hospitals, laboratories may offer more convenient locations and quicker processing times for diagnostic tests, which can result in faster results for patients and physicians. Laboratories primarily cater to the need for routine screening and blood work required for the diagnosis and monitoring of liver diseases.
Regional Insights
The Americas region, particularly the U.S. and Canada, is characterized by the presence of a robust healthcare architecture and favorable reimbursement policies for various disease conditions, thereby fuelling the growth in liver disease diagnostics. Innovations in non-invasive imaging techniques and bio-marker identification are areas where significant investments and patent applications are seen. Initiatives such as the American Liver Foundation's efforts to improve liver health reflect the sector's proactive approach. The European Union displays diverse consumer behavior due to varying healthcare systems and economic capabilities across member countries. However, the adoption of the European Association for the Study of the Liver Clinical Practice Guidelines is a key factor in standardizing liver disease diagnostics. Increased R&D expenditure and multinational collaborations, such as those within the EU Horizon 2020 program, showcase the dynamic environment of innovation in the region. APAC region shows a burgeoning need for liver disease diagnostics due to the growing prevalence of liver-related disorders, growing awareness about liver health, and government initiatives to expand healthcare facilities to marginalized communities. The adoption of digital healthcare services and solutions is also gaining traction in the APAC region, which could create new avenues of growth for the industry.
FPNV Positioning Matrix
The FPNV Positioning Matrix is pivotal in evaluating the Liver Disease Diagnostics Market. It offers a comprehensive assessment of vendors, examining key metrics related to Business Strategy and Product Satisfaction. This in-depth analysis empowers users to make well-informed decisions aligned with their requirements. Based on the evaluation, the vendors are then categorized into four distinct quadrants representing varying levels of success: Forefront (F), Pathfinder (P), Niche (N), or Vital (V).
Market Share Analysis
The Market Share Analysis is a comprehensive tool that provides an insightful and in-depth examination of the current state of vendors in the Liver Disease Diagnostics Market. By meticulously comparing and analyzing vendor contributions in terms of overall revenue, customer base, and other key metrics, we can offer companies a greater understanding of their performance and the challenges they face when competing for market share. Additionally, this analysis provides valuable insights into the competitive nature of the sector, including factors such as accumulation, fragmentation dominance, and amalgamation traits observed over the base year period studied. With this expanded level of detail, vendors can make more informed decisions and devise effective strategies to gain a competitive edge in the market.
Key Company Profiles
The report delves into recent significant developments in the Liver Disease Diagnostics Market, highlighting leading vendors and their innovative profiles. These include Abbott Laboratories, Amgen Inc., Argon Medical Devices, Inc., Bayer AG, Becton, Dickinson and Company, Bio-Rad Laboratories, Inc., BioMerieux SA, Boston Scientific Corporation, Cook Medical Incorporated, Epigenomics AG, F. Hoffmann-La Roche Ltd., Fujifilm Holdings Corporation, Hepatiq, Inc., Hologic, Inc., Horiba, Ltd., Koninklijke Philips N.V., Laboratory Corporation of America Holdings, Medtronic PLC, Merck & Co., Inc., Perspectum Ltd., Quest Diagnostics Incorporated, Randox Laboratories Ltd., Ri.Mos. Srl, Siemens Healthineers AG, and Thermo Fisher Scientific, Inc..
Market Segmentation & Coverage
1. Market Penetration: It presents comprehensive information on the market provided by key players.
2. Market Development: It delves deep into lucrative emerging markets and analyzes the penetration across mature market segments.
3. Market Diversification: It provides detailed information on new product launches, untapped geographic regions, recent developments, and investments.
4. Competitive Assessment & Intelligence: It conducts an exhaustive assessment of market shares, strategies, products, certifications, regulatory approvals, patent landscape, and manufacturing capabilities of the leading players.
5. Product Development & Innovation: It offers intelligent insights on future technologies, R&D activities, and breakthrough product developments.
1. What is the market size and forecast of the Liver Disease Diagnostics Market?
2. Which products, segments, applications, and areas should one consider investing in over the forecast period in the Liver Disease Diagnostics Market?
3. What are the technology trends and regulatory frameworks in the Liver Disease Diagnostics Market?
4. What is the market share of the leading vendors in the Liver Disease Diagnostics Market?
5. Which modes and strategic moves are suitable for entering the Liver Disease Diagnostics Market?